FUNNY_NAME_ALL_CAPS t1_j8trnm6 wrote on February 16, 2023 at 10:01 PM

Interesting, might also explain why SSRIs are known to blunt psychedelic effects.

This also seems to suggest 2A agonism is at least partially related to neuroplastic effects, which would definitely hamper efforts in creating "trip free" derivatives.

I wonder how this relates to 5-HT2A-mGlu2 heterodimers.

hallgod33 t1_j8wtwpw wrote on February 17, 2023 at 2:56 PM

Trip-free derivatives already exist, like bromo-LSD is used for cluster migraines. Shulgin invented a boatload of non-psychedelic analogues to the classical psychedelics.

FUNNY_NAME_ALL_CAPS t1_j8x2ez3 wrote on February 17, 2023 at 3:52 PM

As far as I'm aware 2-bromo-LSD doesn't have antidepressant efficacy. There are now a few substances that labs believe are non-psychoactive and retain antidepressant efficacy, but they base this off mouse head twitch response and they have yet to be validated in humans.

hallgod33 t1_j8x3mjs wrote on February 17, 2023 at 4:00 PM

True that, a lot of Shulgin's work will never be peer reviewed so its hard to elucidate which compounds are providing the effects through human models. And the human models are self-reported and all that. But there are non-psychoactive preparations of a bunch of classical psychedelics that provide anti-depressant effects. What makes it non-psychoactive and effective is hard to pinpoint but Shulgin had a lot of raw data available for anyone interested to explore.